Adcirca

Adcirca is a brand name of tadalafil, approved by the FDA in the following formulation(s):

ADCIRCA (tadalafil - tablet; oral)

• 
  Manufacturer: ELI LILLY CO
  
  Approval date: May 22, 2009
  
  Strength(s): 20MG ^[RLD]

Has a generic version of Adcirca been approved?

No. There is currently no therapeutically equivalent version of Adcirca available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Adcirca. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Tetracyclic derivatives; process of preparation and use
  Patent 5,859,006
  Issued: January 12, 1999
  Inventor(s): Daugan; Alain Claude-Marie
  Assignee(s): ICOS Corporation
  A compound of formula (I) ##STR1## and salts and solvates thereof, in which: R.sup.0 represents hydrogen, halogen or C.sub.1-6 alkyl; R.sup.1 represents hydrogen, C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, haloC.sub.1-6 alkyl, C.sub.3-8 cycloalkyl, C.sub.3-8 cycloalkylC.sub.1-3 alkyl, arylC.sub.1-3 alkyl or heteroarylC.sub.1-3 alkyl; R.sup.2 represents an optionally substituted monocyclic aromatic ring selected from benzene, thiophene, furan and pyridine or an optionally substituted bicyclic ring ##STR2## attached to the rest of the molecule via one of the benzene ring carbon atoms and wherein the fused ring A is a 5- or 6-membered ring which may be saturated or partially or fully unsaturated and comprises carbon atoms and optionally one or two heteroatoms selected from oxygen, sulphur and nitrogen; and R.sup.3 represents hydrogen or C.sub.1-3 alkyl, or R.sup.1 and R.sup.3 together represent a 3- or 4-membered alkyl or alkenyl chain. A compound of formula (I) is a potent and selective inhibitor of cyclic guanosine 3', 5'-monophosphate specific phosphodiesterase (cGMP specific PDE) having a utility in a variety of therapeutic areas where such inhibition is beneficial, including the treatment of cardiovascular disorders.
  
  Patent expiration dates:
  
  
  • November 21, 2017
    
    ✓ 
    Patent use: TREATMENT OF PULMONARY HYPERTENSION
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  



• 
  Beta-carboline drug products
  Patent 6,821,975
  Issued: November 23, 2004
  Inventor(s): Neil R.; Anderson & Kerry J.; Hartauer & Martha A.; Kral & Gregory A.; Stephenson
  Assignee(s): Lilly ICOS LLC
  A compound of structural formula (I), and pharmaceutically acceptable salts and solvates thereof, wherein the compound is in free drug particulate form, is disclosed.
  
  Patent expiration dates:
  
  
  • November 19, 2020
    
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  



• 
  β-carboline pharmaceutical compositions
  Patent 7,182,958
  Issued: February 27, 2007
  Inventor(s): Oren; Peter L. & Anderson; Neil R. & Kral; Martha A.
  Assignee(s): Lilly Icos LLC.
  Formulations containing a PDE5 inhibitor, a water-soluble diluent, a lubricant, a hydrophilic binder, a disintegrant, and optional microcrystalline cellulose and/or a wetting agent, and their use in treating sexual dysfunction, are disclosed.
  
  Patent expiration dates:
  
  
  • April 26, 2020
    
    ✓ 
    Drug product
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • May 22, 2012 - NEW PRODUCT
  
  
  • May 22, 2016 - ORPHAN DRUG EXCLUSIVITY
  
  

See also...

• Adcirca Consumer Information (Drugs.com)
• Adcirca Consumer Information (Wolters Kluwer)
• Adcirca Consumer Information (Cerner Multum)
• Adcirca Advanced Consumer Information (Micromedex)
• Tadalafil Consumer Information (Drugs.com)
• Tadalafil Consumer Information (Wolters Kluwer)
• Tadalafil Consumer Information (Cerner Multum)
• Tadalafil Advanced Consumer Information (Micromedex)
• Tadalafil AHFS DI Monographs (ASHP)